Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...
Stocks that traded heavily or had substantial price changes on Monday: Trimble, CymaBay Therapy rise; Big Lots, Monday
It became increasingly likely that seladelpar will ultimately gain regulatory approval.
The stock has given up some of its gains but remains up more than 130% year to date.
The company is about to reap more money than previously expected from a new capital-raising effort.
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.
The momentum continues after CymaBay reported great clinical results on Thursday.
/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...